Technical Analysis for KROS - Keros Therapeutics, Inc.

Grade Last Price % Change Price Change
D 56.67 -10.70% -6.79
KROS closed down 10.7 percent on Friday, April 16, 2021, on 72 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical KROS trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
50 DMA Support Bullish -10.70%
Upper Bollinger Band Walk Strength -10.70%
Inside Day Range Contraction -10.70%
Upper Bollinger Band Touch Strength -10.70%
50 DMA Support Bullish -7.81%
Older End-of-Day Signals for KROS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% 1 day ago
Down 1 ATR 1 day ago
Down 5% 1 day ago
Fell Below 20 DMA 1 day ago
Fell Below Previous Day's Low 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Keros Therapeutics, Inc. Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Hypertension Disorders Hematology Therapeutic Product Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Syndromes Osteoporosis Genodermatoses Myelodysplastic Syndromes Skeletal Disorders Thrombocytopenia Molecule Product Myelofibrosis Bone Disease Blood Disorders Hematopathology Musculoskeletal Disorders

Is KROS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 88.8
52 Week Low 25.6
Average Volume 124,555
200-Day Moving Average 55.51
50-Day Moving Average 61.34
20-Day Moving Average 59.13
10-Day Moving Average 60.76
Average True Range 4.96
ADX 16.37
+DI 19.83
-DI 18.90
Chandelier Exit (Long, 3 ATRs ) 52.54
Chandelier Exit (Short, 3 ATRs ) 67.37
Upper Bollinger Band 64.55
Lower Bollinger Band 53.71
Percent B (%b) 0.27
BandWidth 18.34
MACD Line 0.00
MACD Signal Line -0.23
MACD Histogram 0.2314
Fundamentals Value
Market Cap 1.31 Billion
Num Shares 23.2 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 613.65
Price-to-Book 13.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.08
Resistance 3 (R3) 71.20 67.85 67.84
Resistance 2 (R2) 67.85 64.43 67.29 67.10
Resistance 1 (R1) 62.26 62.32 60.58 61.14 66.35
Pivot Point 58.91 58.91 58.07 58.35 58.91
Support 1 (S1) 53.32 55.49 51.65 52.20 46.99
Support 2 (S2) 49.97 53.39 49.41 46.24
Support 3 (S3) 44.38 49.97 45.50
Support 4 (S4) 43.26